Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Silence Therapeutics plc (NASDAQ: SLN)
SLN Stock Predictions and Ratings
WSX Rating:
STRONG SELL
WSX Forecast (1yr):
-39.10%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
400%
SLN Stock Analysis
SLN
PE Ratio:
SLN
PEG Ratio:
Not Available
SLN
Forward EPS Growth (12 month):
0.00%
SLN
PS Ratio:
360.9
SLN
PSG Ratio:
Not Available
SLN
Forward Revenue Growth (12 month):
0.00%
SLN Articles
No data was found